@article{HBSN9417,
author = {Zakaria A. Salama and Ahmed Sadek and Ahmed M. Abdelhady and Samar Kamal Darweesh and Shereif Ahmed Morsy and Gamal Esmat},
title = {Losartan may inhibit the progression of liver fibrosis in chronic HCV patients},
journal = {Hepatobiliary Surgery and Nutrition},
volume = {5},
number = {3},
year = {2016},
keywords = {},
abstract = {Background: Abundant experimental evidence indicates overproduction of angiotensin II in the injured liver, and a role in stimulation of hepatic stellate cell (HSC) activation and fibrogenesis thereby, representing an attractive antifibrotic target. The aim of this study was to examine the antifibrotic effect of losartan on histopathologic level in chronic HCV patients.
Methods: A prospective study on fifty patients with chronic HCV and liver fibrosis proved by liver biopsy was conducted. They included patients who did not respond (n=36) or comply (n=2) or receive therapy due to established cirrhosis (n=10), or refused to receive (n=2) combined interferon and ribavirin therapy. They were divided randomly into 2 groups. The 1st group (n=25) was given losartan 50 mg OD for 1 year and the 2nd group (25 patients) was given silymarin, 140 mg t.i.d., (silymarin group). Liver biopsy was done at baseline and 1 year from the onset of treatment (end of study).
Results: In the second liver biopsy after 1 year, the decrease in fibrosis stage was significantly different between losartan group and silymarin group (a decrease of 1.88±0.96 (50.9%) vs. 0.45±0.93 (11.7%), respectively; P},
issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/9417}
}